The efficacy of high-dose 4'epidoxorubicin in hepatocellular carcinoma.

Abstract

An open phase II study of high-dose 4'epidoxorubicin (90 mg/m2) was conducted in 33 patients with inoperable hepatocellular carcinoma. Three out of the 33 (9%) patients showed tumour response. The treatment was relatively well tolerated with a moderate degree of haematological toxicity and alopecia, and a mild degree of nausea and vomiting. The overall median survival was 72 days with a prolongation in the patients who showed some response.

• Authors: W Shiu, N Leung, M Li, W T Leung, A K Li
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 18 Issue 3 Pg. 235-7 (Sep 1988) ISSN: 0368-2811 [Print] England
• PMID: 2842522 (Publication Type: Journal Article)

Chemical References

• Epirubicin
• Doxorubicin

Topics

• Adult
• Aged
• Carcinoma, Hepatocellular (drug therapy)
• Doxorubicin (adverse effects, therapeutic use)
• Epirubicin
• Female
• Humans
• Liver Neoplasms (drug therapy)
• Male
• Middle Aged